A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Public ClinicalTrials.gov record NCT06695845. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)
Study identification
- NCT ID
- NCT06695845
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Enrollment
- 200 participants
Conditions and interventions
Conditions
Interventions
- Zanidatamab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 13, 2025
- Primary completion
- Dec 30, 2026
- Completion
- Dec 30, 2027
- Last update posted
- Apr 8, 2026
2025 – 2027
United States locations
- U.S. sites
- 16
- U.S. states
- 9
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates, PC - NAHOA | Prescott | Arizona | 86301 | Recruiting |
| Rocky Mountain Cancer Center | Littleton | Colorado | 80120 | Recruiting |
| Florida Cancer Specialists - South | Fort Myers | Florida | 33901 | Recruiting |
| Florida Cancer Specialists - Lake Nona | Orlando | Florida | 32827 | Recruiting |
| Florida Cancer Specialists - North | St. Petersburg | Florida | 33705 | Recruiting |
| Florida Cancer Specialists - East | West Palm Beach | Florida | 33401 | Recruiting |
| Affiliated Oncologists | Chicago Ridge | Illinois | 60415 | Recruiting |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | Recruiting |
| Alliance Cancer Specialists | Horsham | Pennsylvania | 19044 | Recruiting |
| Tennessee Cancer Specialists | Knoxville | Tennessee | 37909 | Recruiting |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | Recruiting |
| Texas Oncology - West Texas | Amarillo | Texas | 79124 | Recruiting |
| Texas Oncology - DFW | Dallas | Texas | 75246 | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| Texas Oncology - San Antonio | San Antonio | Texas | 78217 | Recruiting |
| Blue Ridge Cancer Care | Roanoke | Virginia | 24014 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06695845, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 8, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06695845 live on ClinicalTrials.gov.